IRIS
FANIN, Renato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.232
AS - Asia 10.815
EU - Europa 7.531
SA - Sud America 2.161
AF - Africa 264
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 13
Totale 48.036
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.853
SG - Singapore 5.004
CN - Cina 2.361
UA - Ucraina 2.116
BR - Brasile 1.695
DE - Germania 1.129
HK - Hong Kong 1.122
IT - Italia 851
VN - Vietnam 797
FI - Finlandia 795
RU - Federazione Russa 589
SE - Svezia 517
FR - Francia 510
IE - Irlanda 385
IN - India 254
TR - Turchia 241
CA - Canada 238
GB - Regno Unito 238
BD - Bangladesh 190
AR - Argentina 170
KR - Corea 170
IQ - Iraq 114
MX - Messico 80
ZA - Sudafrica 80
CO - Colombia 77
ID - Indonesia 69
PL - Polonia 68
PK - Pakistan 62
EC - Ecuador 61
JP - Giappone 50
NL - Olanda 48
UZ - Uzbekistan 45
AT - Austria 44
ES - Italia 44
IR - Iran 43
VE - Venezuela 37
SA - Arabia Saudita 36
CZ - Repubblica Ceca 33
MA - Marocco 33
CL - Cile 30
PY - Paraguay 29
PE - Perù 27
AE - Emirati Arabi Uniti 26
MY - Malesia 26
BE - Belgio 25
KE - Kenya 25
PH - Filippine 24
EG - Egitto 23
KZ - Kazakistan 20
TG - Togo 20
TN - Tunisia 19
EU - Europa 18
JO - Giordania 18
RO - Romania 18
UY - Uruguay 18
IL - Israele 17
NP - Nepal 17
LT - Lituania 16
BO - Bolivia 15
ET - Etiopia 13
GR - Grecia 13
KG - Kirghizistan 13
OM - Oman 13
RS - Serbia 13
AU - Australia 12
JM - Giamaica 12
TH - Thailandia 12
AL - Albania 10
AZ - Azerbaigian 10
CH - Svizzera 10
LB - Libano 10
DZ - Algeria 9
LV - Lettonia 9
DO - Repubblica Dominicana 8
GE - Georgia 8
PS - Palestinian Territory 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
NI - Nicaragua 7
BH - Bahrain 6
LK - Sri Lanka 6
PT - Portogallo 6
AO - Angola 5
CR - Costa Rica 5
GA - Gabon 5
HU - Ungheria 5
LU - Lussemburgo 5
PA - Panama 5
HN - Honduras 4
RW - Ruanda 4
TW - Taiwan 4
BY - Bielorussia 3
EE - Estonia 3
GT - Guatemala 3
HR - Croazia 3
KH - Cambogia 3
KW - Kuwait 3
LY - Libia 3
NO - Norvegia 3
QA - Qatar 3
Totale 47.972
Salva come PNG Salva come JPEG
Città #
Fairfield 2.978
Woodbridge 2.889
Ashburn 2.016
Houston 1.994
Singapore 1.916
Ann Arbor 1.888
Jacksonville 1.415
Seattle 1.224
Beijing 1.163
Wilmington 1.128
Hong Kong 1.114
Chandler 1.096
San Jose 1.029
Cambridge 977
Dearborn 889
Boardman 484
Council Bluffs 404
Dublin 383
Princeton 381
Dallas 377
Lauterbourg 374
Los Angeles 324
Udine 283
Ho Chi Minh City 247
Buffalo 198
San Diego 189
Hefei 178
Izmir 169
Hanoi 159
New York 157
São Paulo 156
Seoul 153
Santa Clara 132
Munich 129
Helsinki 118
Redondo Beach 111
Ogden 100
Ottawa 98
The Dalles 87
Norwalk 85
Dong Ket 84
Des Moines 81
Frankfurt am Main 70
Trieste 67
Orem 64
Warsaw 61
Montreal 57
Turku 55
Nanjing 54
Mumbai 53
Rio de Janeiro 53
Redmond 50
Toronto 48
Milan 47
Tokyo 44
Nuremberg 42
Pittsburgh 42
Kunming 41
Phoenix 41
Baghdad 40
Tashkent 40
Chennai 38
London 38
Atlanta 37
Johannesburg 35
Belo Horizonte 33
Guangzhou 33
Da Nang 31
Stockholm 31
Chicago 29
Regensburg 29
Denver 28
Dhaka 28
Haiphong 28
Simi Valley 28
Brasília 27
Curitiba 27
Poplar 27
Boston 25
Jinan 25
Rome 25
Brooklyn 24
Brussels 24
Mexico City 24
Porto Alegre 24
Hangzhou 23
Nanchang 23
Shanghai 23
Quito 22
Amsterdam 21
Guayaquil 21
Nairobi 21
Saint Petersburg 21
Vienna 21
Düsseldorf 20
Leawood 20
Manchester 20
Bogotá 19
Campinas 19
Lomé 19
Totale 31.337
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 281
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 241
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 226
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 212
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 210
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 207
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 207
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 204
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 201
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 197
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 197
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 197
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 192
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 191
Atypical haemolytic-uraemic syndrome at the onset of acute promyelocytic leukaemia. 190
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study 189
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 188
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 187
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 184
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 183
Multipotent Progenitor Cells Are Present in Human Peripheral Blood. 183
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 181
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 180
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 179
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 179
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 178
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 178
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 176
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 176
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 175
P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. 175
A comparison of allografting with autografting for newly diagnosed myeloma 175
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 174
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells 174
Multipotent Mesenchymal Stem Cells Can Be Isolated and Grown from Many Tissues (Bone Marrow, Liver and Heart) 172
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 171
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 171
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 170
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 169
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 168
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 167
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 167
Family history of cancer and risk of second malignancies in young cancer patients in Trieste, Italy. 166
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 166
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 165
Management of immune thrombocytopenia in elderly patients 165
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 165
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 163
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 161
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 161
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 160
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 159
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 159
Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome. 158
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 158
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. 158
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 158
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 158
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 157
“Overexpression of multidrug resistance-associated P-170 glycoprotein in acute non lymphocytic leukemia”. 156
Autologous stem cell transplantation in chronic carriers of hepatitis B virus and hepatitis C virus affected by onco-hematologic diseases. 156
Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience 156
Rituximab for the treatment of type II mixed cryoglobulinemia. 155
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 154
Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). 154
Late onset cytomegalovirus encephalitis after reduced-intensity conditioning allogeneic SCT: an emerging neurological complication? 154
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. 154
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 154
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 154
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 154
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 153
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation 152
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. 152
Unexpected phenotype of a typical NPM1 mutant 152
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 152
Acute promyelocytic leucemia: low expression of multidrug resistance phenotype at onset suggest a favourable effect of gentuzumab ozogamicyn (CMA-676 151
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 151
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 151
Pre-Chemotherapy risk factors for invasive fungal diseases: Prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (seifem 2010-a multicenter study) 151
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 151
Granulocyte-macrophage colony -stimulating factor in acute nonlymphocytic leukemia before and after chemo therapy”. 150
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 150
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. 149
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 149
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 148
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 148
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 148
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 147
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 147
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 147
Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. 146
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 146
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. 146
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 146
KIR POLYMORPHISM IN REDUCED INTENSITY HLA-ID SIBLING STEM CELL TRANSPLANTATION: IMPACT ON CLINICAL OUTCOME 145
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 145
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 145
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 145
Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases 145
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. 144
Totale 16.812
Salva come PNG Salva come JPEG
Categoria #
all - tutte 180.203
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 180.203
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021294 0 0 0 0 0 0 0 0 0 0 0 294
2021/20223.087 116 364 156 225 93 142 183 143 56 505 629 475
2022/20232.796 418 157 31 324 257 824 14 203 382 37 85 64
2023/2024849 121 66 27 27 132 99 17 52 142 65 32 69
2024/20256.850 149 501 380 169 292 308 404 424 664 602 1.090 1.867
2025/202613.147 1.002 1.464 1.116 1.328 1.858 1.065 1.577 434 1.005 1.270 809 219
Totale 49.119